Tesamorelin Protocol: How to Cycle It, Timing & What to Expect

Protocol snapshot

• Typical cycle length: 8 to 12 weeks active, followed by a structured off-cycle break; longer clinical protocols run up to 26 weeks under medical supervision
• Frequency: Once daily subcutaneous injection; some protocols use five days on, two days off as a practical variation
• Common delivery routes: Subcutaneous injection only
• Key timing notes: Evening injection, 30 to 90 minutes before sleep, at least two to three hours after the last meal; consistency of timing matters more than the exact clock time

Who This Protocol Is For

Tesamorelin draws a specific kind of interest. People who look into it are usually not chasing a general body composition fix. They have a particular target: visceral fat, the deep abdominal fat that sits around organs and resists most conventional approaches. That narrow, specific goal is what makes this peptide distinct and why the protocol conversation around it looks different from most others.

The most common goal driving a Tesamorelin protocol is visceral fat reduction. Visceral fat is not the soft fat you can pinch under the skin. It is the harder, deeper layer wrapped around the abdominal organs, and it is a meaningful driver of metabolic risk. Clinical trials established that Tesamorelin works on this target specifically, not just subcutaneous fat in general. That clinical anchor is what the protocol is built around.

Beyond the primary fat-loss goal, a meaningful share of people running Tesamorelin are focused on metabolic health more broadly: improving energy, supporting body composition changes that the scale may not fully capture, and the longer-arc benefits that accumulate over several months of consistent use. Longevity-focused users and those working with functional medicine clinicians make up a significant part of the off-label use population.

Experience level matters here in a specific way. This is not a compound where a beginner and an advanced user run identical protocols. The titration phase at the start of the cycle is genuinely important for tolerability, and users who skip it tend to experience more side effects early on. Delivery method does not vary: Tesamorelin is administered by subcutaneous injection only. There is no oral, nasal, or topical route with established efficacy for this compound.

How Is a Tesamorelin Cycle Structured?

A Tesamorelin cycle has a clear three-part shape: a titration phase at the opening, a maintenance phase that carries the bulk of the active period, and an off-cycle break that closes the loop before the next cycle begins.

The titration phase comes first. Rather than starting at a full maintenance level from day one, most real-world protocols build the dose gradually over the first two to four weeks. This is about tolerability: it allows the body to adapt to rising growth hormone activity before reaching the target level. Think of it like letting an engine warm up before pushing it to highway speed. Joint discomfort, mild water retention, and appetite changes are considerably more pronounced when someone starts at the full maintenance level from the beginning, which is why the step-up approach is the norm in functional practice.

The maintenance phase then runs for the remainder of the active cycle. Most functional protocols put the total active period at 8 to 12 weeks, though Tesamorelin's Phase 3 trials ran continuously for up to 26 weeks. The maintenance phase is where the meaningful visceral fat reduction accumulates, and consistency is the variable that matters most.

The off-cycle break rounds out the structure. Breaks are a standard part of how Tesamorelin is run outside of formal clinical settings. The overall pattern is a defined active period followed by a defined rest, then repeat. The full rationale for off-cycle breaks is in the Off-Cycle Considerations section.

How Your Dose Is Determined

What moves a Tesamorelin dose:

• Your goal: Tesamorelin is run primarily for visceral fat reduction, with improved metabolic markers and body composition following from that. Goals within that range still shift where someone lands. Those pursuing general metabolic optimization and longevity tend toward the lower end of the range, where IGF-1 (insulin-like growth factor 1, the downstream signal that drives visceral fat metabolism) rises meaningfully without pushing to the ceiling. Those targeting more aggressive visceral fat reduction or working within a formal clinical context tend toward the higher end.
• Experience level: Someone new to this compound almost always starts at the lower end and titrates upward over several weeks. A more experienced user with established tolerance may move through the titration phase more quickly, though the ceiling for most users is the same regardless of experience.
• Delivery route and injection pattern: Tesamorelin is subcutaneous injection only, so there is no route-based dose adjustment. What does shift is whether the daily total is taken as a single evening injection or split across two administrations. Most protocols use a single daily injection in the evening. Some advanced users and certain clinic protocols split the daily dose into a morning and evening injection, though the single evening approach aligns better with the nocturnal GH pulse rationale.
• Individual response: IGF-1 levels vary significantly between individuals at the same dose. Two people can run identical protocols and land in meaningfully different places on their lab values. Blood work, particularly IGF-1 monitoring, is the honest signal for how an individual is actually responding, and that data is what experienced practitioners use to refine the dose over time.

There is no single dose that fits everyone running a Tesamorelin protocol. The factors above interact, and the right number sits at the intersection of goal, tolerance, and individual response. The titration phase exists precisely because starting at the top of the range without accounting for individual tolerance is one of the most common mistakes for this compound.

Your dose should not be a guess. The MyPeptidePal Protocol Creator takes your visceral fat reduction goal, your experience level with the titration phase, and whether you run a single evening injection or a split daily dosing pattern and builds your Tesamorelin protocol: your dose, your cycle, and your timing.

Get your protocol at mypeptidepal.ai

How Often Do You Take Tesamorelin?

Tesamorelin is injected once daily in the vast majority of protocols. The case for daily dosing is straightforward: IGF-1 accumulates over time, and consistent daily administration is what produces the cumulative elevation that drives visceral fat reduction. Phase 3 trials used uninterrupted daily dosing throughout, and that is the foundation the efficacy data rests on. A five-days-on, two-days-off pattern is common in functional medicine practice because it is practical and generally well-tolerated, but the trade-off is real: weekday-only dosing reduces IGF-1 accumulation compared to daily dosing.

Timing within the day matters more for this compound than for most peptides. The target window is 30 to 90 minutes before sleep, with the last meal at least two to three hours prior. The body releases GH (growth hormone) in a natural nocturnal pulse during deep sleep. Tesamorelin prompts the pituitary to release GH, and taking it in the evening aligns that prompt with the body's existing rhythm, amplifying the effect. Injecting in the morning misses this window entirely. Insulin from a recent meal also blunts GH secretion, which is why the fasted-before-sleep window is specifically recommended rather than just any evening time.

Consistency of timing is the other critical principle. Injecting at the same time every evening supports stable pituitary rhythm and steady IGF-1 accumulation. Varying the injection time day to day disrupts both.

Loading and Maintenance Phases

Tesamorelin does not use a loading phase in the traditional sense, where a higher initial dose front-loads the compound. The titration phase at the start of a cycle is the opposite structure: it begins below the maintenance level and steps up gradually.

The titration phase covers the first two to four weeks of a cycle. A common approach across functional medicine protocols starts below the full maintenance level and increases in increments roughly every week until the maintenance level is reached. The purpose is tolerability. Once the full maintenance level is reached, the dose holds there for the remainder of the active cycle. The dose is consistent across the maintenance phase; there is no further stepping up or ramping down within it.

The maintenance phase is where the work happens. For 8-week protocols, maintenance occupies the majority of the cycle after a shorter titration window. For 12-week or longer protocols, there is more time at the maintenance level and cumulative IGF-1 exposure builds further. Phase 3 clinical trials used a compressed titration, one week at a lower level, followed by continuous daily maintenance dosing through 26 weeks. The more gradual multi-week titration approach common in functional practice is a community refinement aimed at reducing early side effects rather than a clinically validated adjustment, but it is well-supported across practitioner and user protocols.

Once the active cycle ends, the compound is stopped without a taper down. The off-cycle break follows directly.

Off-Cycle Considerations

Taking a break from Tesamorelin is standard practice in functional and community protocol settings, even though the clinical trials ran patients continuously for up to 52 weeks without a mandated rest period. The clinical population was HIV patients under ongoing medical supervision. For off-label functional use, the cycling rationale is grounded in three concerns.

First, receptor sensitivity: sustained stimulation of the same pituitary receptors over a long period can lead to diminished response, and a break allows those receptors to reset before the next cycle begins. Second, antibody formation: some users who run Tesamorelin for extended periods develop neutralizing antibodies to the peptide, which can reduce its effect over time. Structured cycling is the practical way to manage that risk. Third, natural GH rhythm: a break allows the body's endogenous GH secretion to reassert its natural pulsatility, which may be partially suppressed during an active cycle.

The most commonly observed off-cycle structures in functional practice are a one-month break after a three-month active cycle, a two-month break after a three-month active cycle for those prioritizing receptor recovery, or a matched eight-weeks-on, eight-weeks-off pattern that some practitioners favor for balancing efficacy and receptor preservation. The longer the active cycle, the more a proportionally longer break makes sense.

One detail worth noting: some of the visceral fat reduction achieved during a well-run Tesamorelin cycle may be durable beyond the off-cycle period, particularly when lifestyle habits are maintained. The off-cycle is not a reversal of results. It is a reset before the next active phase.

What to Expect Week by Week

• Week 1 to 2: The most commonly reported early effects are subjective: slightly improved sleep quality, a mild sensation of warmth at night, and in some users a modest uptick in appetite. Visible fat loss is not expected yet. The body is adapting to rising GH activity. Some mild water retention is possible during this window, particularly as the dose steps up, and it generally resolves within days.
• Week 3 to 4: Users commonly report a reduction in the feeling of abdominal tightness, with some noting the waist feels slightly smaller even before any meaningful change shows on the scale. This is consistent with early visceral fat reduction beginning. Subcutaneous fat in the abdomen may begin to feel softer.
• Week 5 to 8: More meaningful change commonly appears in this window. Clinical data from Phase 3 trials showed approximately 1.5 to 2 centimeter waist circumference reduction versus placebo in this range. Users consistently report visible girth reduction, improved belt fit, and in some cases better-fitting clothes around the midsection despite stable or unchanged body weight on the scale.
• Beyond 8 weeks: For those running 12-week or longer cycles, the months-three-through-six window is where the fuller picture emerges. Enhanced energy, improved cognitive clarity, and deeper visceral fat loss are commonly reported. Phase 3 trials found 15 to 18 percent visceral adipose tissue reduction at 26 weeks of continuous daily dosing, which is the benchmark for what a well-run extended protocol can achieve.

What a well-run Tesamorelin cycle commonly looks like when it goes right: a user with consistent evening injection timing, a proper titration in the first two to three weeks, and sound nutritional habits through the cycle typically begins to notice the waist slimming around weeks four to six. By weeks eight to ten, clothes fit differently, and DEXA data at the three-month mark commonly shows measurable visceral fat reduction that the scale alone would not capture. The subjective sense of improved energy and metabolic engagement builds progressively rather than arriving all at once. These are commonly reported arcs drawn from clinical data and user experience, not guarantees, and individual results vary based on consistency, lifestyle, and individual response.

Common Protocol Mistakes

Injecting in the morning. Tesamorelin's mechanism is specifically built around amplifying the nocturnal GH pulse. Morning injection misses that window and reduces the compound's effectiveness. The evening injection is not a preference; it is central to how the protocol works.

Inconsistent timing. Injecting at different times each day disrupts pituitary rhythm and reduces the cumulative IGF-1 accumulation that drives results. The same time every evening is the principle. Regular inconsistency compounds into meaningfully reduced outcomes over the course of a cycle.

Starting at the full maintenance dose. Joint discomfort, water retention, and appetite changes are substantially more pronounced when someone starts at the clinical trial dose from day one. The titration phase exists to manage this. Skipping it does not produce faster results; it produces more side effects and often leads to early discontinuation.

Doubling up after a missed dose. Taking twice the usual amount the following day does not recover the missed dose's benefit and meaningfully increases side effect risk. The correct approach is to skip the missed dose and resume the normal schedule the following evening.

Rough handling during reconstitution. Tesamorelin is a peptide, and vigorous shaking degrades its structure and leads to reduced efficacy. Gentle handling is essential; confirm the correct reconstitution technique with a qualified source before use.

Injecting into the same site repeatedly. Rotating injection sites is not optional. Repeated injection into the same spot causes tissue damage, nodule formation, and reduced absorption over time. Avoid the navel itself and any area that is scarred, bruised, inflamed, or has hard spots from prior injections.

Improper storage. Reconstituted Tesamorelin requires refrigeration to maintain stability and potency. Follow the storage guidance for the specific formulation being used.

Stacking with another GHRH (growth hormone-releasing hormone) compound. Combining Tesamorelin with another peptide that works through the same GHRH receptor adds redundant stimulation without proportional benefit and increases the risk of excessive GH elevation. If stacking is part of the plan, a peptide that works through a complementary mechanism, specifically the ghrelin receptor, is the approach favored in functional practice and should be run with qualified oversight.

Tesamorelin holds FDA approval only for HIV-associated lipodystrophy. Off-label use for body composition and metabolic optimization falls outside that approval. Users who compete in tested sports should verify current WADA status independently before use.

Frequently Asked Questions

How long is a typical Tesamorelin cycle?

Functional protocols typically run 8 to 12 weeks of active dosing, followed by a structured off-cycle break before repeating. Longer cycles up to 26 weeks are seen in clinical settings under medical supervision. The right cycle length depends on the individual's goal, response, and supervision context, and the MyPeptidePal Protocol Creator builds that detail into a personalized plan.

How often do you take Tesamorelin?

Most protocols use once-daily subcutaneous injection, taken 30 to 90 minutes before sleep and at least two to three hours after the last meal. Some functional medicine protocols use a five-days-on, two-days-off pattern as a practical convenience, though daily dosing produces more consistent IGF-1 accumulation. The injection time should be kept consistent from day to day.

Does Tesamorelin need a loading phase?

Not in the traditional higher-dose loading sense. Tesamorelin protocols use a titration phase that starts below the maintenance level and steps up gradually over two to four weeks. This is the opposite of a loading phase. The gradual build is specifically about tolerability: starting at the full maintenance level from day one significantly increases the likelihood of early side effects like joint discomfort and water retention.

Do you need to cycle off Tesamorelin?

In functional and community practice, yes. Off-cycle breaks are standard and are used to preserve receptor sensitivity, reduce the risk of antibody development, and allow the body's natural GH rhythm to reassert itself before the next active phase. Clinical trials used continuous daily dosing for up to 52 weeks without mandated breaks, but that was a specific medical context under ongoing supervision. For most off-label use, cycling is the norm.

Can Tesamorelin be stacked with other peptides?

Yes, but with a clear principle: the complementary peptide should work through a different mechanism. Tesamorelin acts on the GHRH receptor. Pairing it with a peptide that acts on the ghrelin receptor produces synergistic pulsatile GH release without redundant stimulation. Combining it with another GHRH-acting compound creates overlapping signals without proportional benefit and increases side effect risk. Any stacking approach should be run with qualified oversight.

Why is evening timing so important for Tesamorelin?

The body releases GH naturally in a pulse during deep sleep. Tesamorelin prompts the pituitary to release GH, and taking it in the evening aligns that signal with the body's existing nocturnal rhythm rather than working against it. Morning injection misses this window. Eating close to injection time also blunts the response, because elevated insulin from a recent meal suppresses GH secretion. The combination of evening timing and a fasted window before injection is what lets the protocol work as designed.

Disclaimer

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world protocols for Tesamorelin in one place.